In the PIONEER-HF trial comparing the in-hospital initiation of sacubitril/valsartan versus enalapril in patients with heart failure with reduced ejection fraction, the use of sacubitril/valsartan reduced NT-proBNP level by 47% and BNP level by 29% from baseline [24]. The gene discussed is NPPB; the disease is hydrops fetalis.